Product Images Mirabegron

This text provides information on the effects of different drugs on the pharmacokinetics (PK) of Mirabegron. It lists examples of CYP3A/Pgp inhibitors/inducers, their recommended dosages, and the fold change in AUC and Cmax. The drugs mentioned include Ketoconazole, Rifampicin, Salifenacin, Tamsulosin, and Metformin. The data suggests whether dose adjustments are necessary with Mirabegron when co-administered with these medications.*

This is a list showing changes from baseline values for different time points in a study comparing a placebo group with a group receiving 50 mg of mirabegron. The data includes mean changes and sample sizes for each group at different weeks.*

This is a comparison chart showing the mean change from baseline in a study evaluating the effectiveness of Mirabegron 50 mg compared to a placebo over a certain period of time. The chart includes data points at different intervals and specifies the number of participants for each group.*

This is a set of numbers indicating a decrease from baseline scores in a study comparing placebo with mirabegron 50mg. The sample size for placebo is 325 and for mirabegron 50mg is 312. The mean change from baseline is decreasing in value.*

This is a table showing the mean change from baseline for different time points in a study comparing mirabegron (25mg and 50mg) to a placebo. The changes in values are displayed at intervals ranging from 0.00 to -2.00 over the course of the study.*

This text appears to be a table showing numerical values of mean changes from baseline for different treatments and time points. It also includes information about the number of participants for each treatment group. The data includes values ranging from -1.75 to -2.25 with references to placebo, mirabegron 25 mg, and mirabegron 50 mg. The table seems to be related to a clinical trial or study evaluating the efficacy of mirabegron at different doses over time.*

This is a description for a medication named "Mirabegron." The tablets come in a pack with NDC 68180-151-06. The typical dosage is once a day taken orally. Storage instructions include storing at room temperature and protecting from excursions (permitted within a specified range). The manufacturer is identified as Lupin Pharmaceuticals, Inc., located at Baltimore, Maryland. The tablets should be swallowed whole and not cut, crushed, or chewed. It is an extended-release formulation and should be kept out of reach of children. There are 30 tablets per pack.*

This is a medication package insert for Mirabegron Extended-Release Tablets, with a dosage of 25 mg. It is intended for once-daily use and should be swallowed whole without cutting, crushing, or chewing. The tablets should be stored at room temperature. The product is manufactured by Lupin Pharmaceuticals and dispensed in a tight container with safety closures. The text also includes information about the manufacturer's address and contact details.*

This text provides information about a medication with the NDC 68180-152-06, containing 50 mg of mirabegron per tablet. The recommended dosage is once daily by mouth. It advises against cutting, crushing, or chewing the tablet, and to swallow it whole. The tablets are extended-release and should be stored at 25°C (77°F), with excursions permitted to 15°C to 30°C. The medication should be kept out of reach of children. The product is manufactured by Lupin Limited, and the package contains 30 tablets. *

The text is not clearly readable.*